Boston Scientific, a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices, agreed to acquire Obsidio, a privately-held company that has developed the Gel Embolic Material technology used for embolization of blood vessels in the peripheral vasculature. Financial terms were not disclosed. "The GEM technology combines benefits of currently available embolics, such as precise control of a solid and malleability of a liquid, to create a unique technology that offers procedural efficiency and a more personalized therapy for patients. This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions," Peter Pattison, Boston Scientific President, Interventional Oncology and Embolization, Peripheral Interventions.